• Shares of Biogen’s hemophilia spinoff Bioverativ began trading today on a “when issued” basis and will begin regular trading on February 2nd under the BIVV symbol. The company gets started with about 400 staffers under CEO John Cox at a time a number of gene therapies in the clinic look to disrupt the field.
• Jamie Freedman is taking over as the new head of oncology at AstraZeneca after Mondher Mahjoubi left to join Innate. Freedman is coming in from the pharma giant’s MedImmune subsidiary. Earlier he had worked at GSK and OPKO Health, reports PMLive.
• Shire is paying a $350 million fine to settle a DoJ suit over its use of illegal kickbacks to persuade doctors to prescribe their meds.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription